Big Think
It may not yet be the gene-editing world we may have imagined when we first learned of CRISPR-Cas9, but it looks like 2018 may be the year that future finally gets underway at last. Finally, human trials are about to get underway in Europe and the U.S. The targets of the these trials are two genetic blood disorders that ruin hemoglobin: sickle-cell anemia and beta thalassemia.
Achieve breakthrough lifespan, augment your abilities and shatter your comfort zone. Attend Superhuman Summit and experience a future-thinking educational showcase that will advance your human potential.
Reserve